All In Biotech

Drug Trial Radar · NCT07073547

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

A Modular, Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120, a Dual-targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19 in Participants With Multiple Myeloma (DURGA-2)

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jul 31, 2025

Primary completion

May 26, 2028

Study completion May 26, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM).

Conditions

  • Multiple Myeloma

Interventions

  • AZD0120Biological

    AZD0120 is a BCMA/CD19 dual CAR T cell product under investigation for early-line treatment in subjects with multiple myeloma

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events (AEs)Time frame: 2 years
  2. Serious Adverse Events (SAEs)Time frame: 2 years
  3. Dose Limiting Toxicities (DLT)Time frame: 28 days

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona · Withdrawn

  • Research Site

    Duarte, California · Recruiting

  • Research Site

    Denver, Colorado · Recruiting

  • Research Site

    Tampa, Florida · Active not recruiting

  • Research Site

    Atlanta, Georgia · Recruiting

  • Research Site

    Iowa City, Iowa · Recruiting

  • Research Site

    Rochester, Minnesota · Withdrawn

  • Research Site

    St Louis, Missouri · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Nashville, Tennessee · Recruiting

  • Research Site

    Dallas, Texas · Withdrawn

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    Charlottesville, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.